Products - Thyroid disorders | Topic | NICE

Showing 3 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Vandetanib for treating medullary thyroid cancer (TA550)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2018
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Cabozantinib for treating medullary thyroid cancer (TA516)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2018